Article By:
ChinaBio® Today
Saturday, June 20, 2020 2:04 PM EDT
Immvira Group, a Shenzhen biotech developing oncolytic virus therapies, completed a $58 million Series B financing. Miaoshou Doctor, an online-offline healthcare company headquartered in Beijing, closed an $85 million Series D1 round.